Adamas Pharmaceuticals, Inc. (ADMS) Upgraded to Hold by Zacks Investment Research

Zacks Investment Research upgraded shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) from a sell rating to a hold rating in a report published on Tuesday.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

Several other brokerages have also recently issued reports on ADMS. Noble Financial reissued a buy rating and set a $33.00 price objective on shares of Adamas Pharmaceuticals in a research note on Friday, September 29th. BidaskClub raised shares of Adamas Pharmaceuticals from a strong sell rating to a sell rating in a research note on Wednesday, August 23rd. Mizuho reissued a buy rating and set a $26.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, September 5th. Piper Jaffray Companies reissued an overweight rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a research note on Friday, September 1st. They noted that the move was a valuation call. Finally, JMP Securities reissued an outperform rating and set a $33.00 price objective (up from $29.00) on shares of Adamas Pharmaceuticals in a research note on Friday, August 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $39.50.

Adamas Pharmaceuticals (ADMS) opened at 21.69 on Tuesday. The firm’s 50-day moving average price is $20.71 and its 200-day moving average price is $17.68. Adamas Pharmaceuticals has a 1-year low of $12.10 and a 1-year high of $24.18. The firm’s market capitalization is $488.33 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. During the same period in the previous year, the company earned ($0.78) earnings per share. The firm’s revenue for the quarter was down 90.9% on a year-over-year basis. On average, equities research analysts predict that Adamas Pharmaceuticals will post ($3.77) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.themarketsdaily.com/2017/10/11/adamas-pharmaceuticals-inc-adms-upgraded-to-hold-by-zacks-investment-research.html.

A number of institutional investors have recently made changes to their positions in ADMS. Wells Fargo & Company MN boosted its position in Adamas Pharmaceuticals by 28.4% during the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after purchasing an additional 3,358 shares during the period. Bank of New York Mellon Corp boosted its position in Adamas Pharmaceuticals by 2.4% during the 1st quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock worth $1,152,000 after purchasing an additional 1,563 shares during the period. Parametric Portfolio Associates LLC boosted its position in Adamas Pharmaceuticals by 153.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock worth $1,956,000 after purchasing an additional 67,654 shares during the period. American International Group Inc. boosted its position in Adamas Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after purchasing an additional 682 shares during the period. Finally, Vanguard Group Inc. boosted its position in Adamas Pharmaceuticals by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock worth $12,537,000 after purchasing an additional 66,825 shares during the period. 69.16% of the stock is owned by hedge funds and other institutional investors.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply